Etoricoxib 202409-33-4 98%

Glenmark Pharmaceuticals Limited is a research‐led, global pharmaceutical company, having a presence across branded, generics, and OTC segments; with a focus in the therapy areas of Respiratory, Dermatology and Oncology. The company has four research and development centres, ten world‐class manufacturing facilities spread across five continents, and operations in over eighty countries.

In its quest to be among the first few Indian pharmaceutical companies to develop an innovative drug for the world, Glenmark is treading two parallel paths. One pursues the discovery of a novel chemical or biological entity. The second that leads towards scaling the value chain by creating specialty products, like RYALTRIS®, that address gaps in treatment.

Glenmark Pharmaceuticals and its fully owned US subsidiary Ichnos Sciences together have formed an alliance ‘Ichnos Glenmark Innovation’ to use different modalities, technologies and combined expertise to treat cancer. It has a robust pipeline of innovative molecules, in various stages of clinical development across oncology and immunology.

Glenmark is driven by a continuous commitment to create ‘A New Way for a New World’. Harnessing the potential of our core strengths of innovation, research, and scientific knowledge, we remain determined to consistently challenge established treatment paradigms. It allows us to identify and deliver promising solutions that make a considerable difference to the lives of patients in diverse geographies.